MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities
Provided By GlobeNewswire
Last update: Aug 14, 2025
ROCKVILLE, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and highlighted recent corporate progress.
Read more at globenewswire.com
